One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Celcuity  logo
Celcuity CELC
$ 67.13 -4.5%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Celcuity Income Statement 2025-2011 | CELC

Annual Income Statement Celcuity

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

5.37 B 399 M 430 M 163 M 135 M 150 M 118 M 224 M 135 M - - - - - -

Shares

46.8 M 39.4 M 23.7 M 15.4 M 13.4 M 10.3 M 10.2 M 10.1 M 7.46 M - - - - - -

Historical Prices

115 10.1 18.2 10.6 10.1 14.2 8.49 22.3 17.3 - - - - - -

Net Income

-177 M -112 M -63.8 M -40.4 M -29.6 M -9.47 M -7.36 M -7.48 M -6.25 M -3.31 M -2.26 M - - - -

Operating Income

-172 M -113 M -66.2 M -39.4 M -28.4 M -9.56 M -7.81 M -7.93 M -5.95 M -3.33 M - - - - -

Interest Expense

- - 5.33 M 2.11 M 1.26 M 120 159 111 452 K - - - - - -

EBITDA

-172 M -113 M -66.1 M -39.2 M -28.1 M -9.17 M -7.47 M -7.71 M -5.85 M -3.26 M -2.2 M - - - -

Operating Expenses

172 M 113 M 66.2 M 39.4 M 28.4 M 9.56 M 7.81 M 7.93 M 5.95 M - - - - - -

General and Administrative Expenses

27.2 M 9.06 M 5.64 M 4.1 M 2.6 M 1.87 M 1.54 M 1.61 M 973 K 264 K 250 K - - - -

All numbers in USD currency

Quarterly Income Statement Celcuity

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

55.1 M 54.8 M 54.5 M 1.97 M 47.6 M 43.7 M 43.1 M 1.15 M 42.8 M 38.4 M 33.6 M 1.76 M 22.1 M 22 M 21.7 M 490 K 14.9 M 14.9 M 14.9 M 515 K 14.9 M 12.6 M 11.1 M 4.25 M 10.3 M 10.3 M 10.3 M 8.6 M 10.2 M 10.2 M 10.2 M 10.2 M 10.1 M 10.1 M 10.1 M 883 K 6.85 M 6.44 M 6.44 M - 6.44 M - - - - - - - - - - - - - - - - - - - - - -

Net Income

-73.3 M -78.9 M -52.8 M -51 M -43.8 M -45.3 M -37 M -36.7 M -29.8 M -23.7 M -21.6 M -18.8 M -18.4 M -14.6 M -11.9 M -11.6 M -10.9 M -9.96 M -7.93 M -6.75 M -6.03 M -14 M -2.79 M -2.55 M -2.47 M -2.2 M -2.25 M -1.81 M -1.98 M -1.72 M -1.85 M - -1.87 M -1.82 M -1.97 M -1.72 M -1.76 M -1.78 M -987 K - -3.31 M - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-77.3 M -66.1 M -50.5 M -49.2 M -42.8 M -44 M -36.1 M -36.4 M -30.1 M -24.3 M -22.5 M -19.7 M -18.9 M -15.1 M -12.5 M -11.6 M -10.6 M -9.6 M -7.51 M -6.32 M -5.6 M -13.6 M -2.79 M -2.55 M -2.48 M -2.21 M -2.31 M -1.9 M -2.09 M -1.84 M -1.97 M - -1.98 M -1.93 M -2.08 M -1.82 M -1.53 M -1.61 M -994 K - -878 K - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - 268 K 561 K 881 K 881 K 493 K 468 K 609 K 57.9 K -250 K -360 K -427 K -433 K -427 K -389 K 24 443 5.78 K 12 K 33 36 39 41 43 - 65 - - - 265 K 187 K - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-77.3 M -66.1 M -50.5 M -49.2 M -42.8 M -44 M -36.1 M -36.4 M -30 M -24.3 M -22.5 M -19.7 M -18.9 M -15 M -12.5 M -11.6 M -10.6 M -9.55 M -7.45 M -6.26 M -5.54 M -13.5 M -2.69 M -2.45 M -2.38 M -2.02 M -2.22 M -1.8 M -2 M -1.76 M -1.9 M - -1.91 M -1.88 M -2.04 M -1.8 M -1.5 M -1.58 M -974 K - -859 K - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

77.3 M 66.1 M 50.5 M 49.2 M 42.8 M 44 M 36.1 M 36.4 M 30.1 M 24.3 M 22.5 M 19.7 M 18.9 M 15.1 M 12.5 M 11.6 M 10.6 M 9.6 M 7.51 M 6.32 M 5.6 M 13.6 M 2.79 M 2.55 M 2.48 M 2.21 M 2.31 M 1.9 M 2.09 M 1.84 M 1.97 M - 1.98 M 1.93 M 2.08 M 1.82 M 1.53 M 1.61 M 994 K - 878 K - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

39.8 M 35 M 17.4 M 805 K 12.4 M 7.59 M 6.37 M 2.96 M 2.47 M 1.79 M 1.85 M 1.65 M 1.41 M 1.31 M 1.27 M 1.04 M 1.02 M 1.23 M 811 K 830 K 639 K 573 K 555 K 444 K 517 K 448 K 463 K 401 K 380 K 372 K 384 K - 377 K 383 K 531 K 421 K 165 K 302 K 85.1 K - 64.7 K - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Celcuity (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Co-Diagnostics Co-Diagnostics
CODX
$ 0.29 -9.5 % $ 386 K usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 13.19 6.46 % $ 135 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 2.37 15.05 % $ 9.44 M israelIsrael
Myriad Genetics Myriad Genetics
MYGN
$ 5.66 -1.39 % $ 524 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.78 -1.24 % $ 3.76 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
$ 50.52 -0.07 % $ 11 B niderlandNiderland
NeoGenomics NeoGenomics
NEO
$ 16.97 -3.58 % $ 2.17 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.71 0.58 % $ 1.28 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 2.22 -5.93 % $ 666 M usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 11.67 -3.44 % $ 2.54 B usaUSA
Precipio Precipio
PRPO
$ 23.56 6.13 % $ 37.8 M usaUSA
Personalis Personalis
PSNL
$ 15.9 -0.31 % $ 1.42 B usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 16.25 -1.16 % $ 4.61 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 11.56 -4.43 % $ 487 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 5.88 10.08 % $ 2.11 B irlandaIrlanda
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 26.91 0.9 % $ 602 M usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 132.17 -2.35 % $ 7.9 B usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Waters Corporation Waters Corporation
WAT
$ 476.29 -0.09 % $ 28.4 B usaUSA
Exagen Exagen
XGN
$ 5.26 -25.92 % $ 113 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 370.89 -0.25 % $ 30.9 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 101.65 0.63 % $ 6.86 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 664.97 -1.18 % $ 19.2 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 346.21 -2.02 % $ 17.2 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 750.2 -0.69 % $ 36.1 B schweizSchweiz
Danaher Corporation Danaher Corporation
DHR
$ 236.19 0.46 % $ 168 B usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 30.39 -1.32 % $ 28.8 B niderlandNiderland
RadNet RadNet
RDNT
$ 77.91 -0.6 % $ 5.86 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 10.05 2.55 % $ 419 M usaUSA
Neuronetics Neuronetics
STIM
$ 2.01 -7.8 % $ 133 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 719.09 -0.35 % $ 271 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Guardant Health Guardant Health
GH
$ 155.43 -2.12 % $ 19.5 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 10.63 -8.68 % $ 361 M israelIsrael